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The ability of a xenobiotic substance to
induce protection against subsequent exposure
and also to induce protection against exposure
to other potentially toxic compounds was first
described more than 30 years ago by Hans
Selye (1971). It was quickly realized that such
“catatoxic” compounds led to an increase in
hepatic cytochrome P450 (CYP) enzyme
activity (Einarsson and Gustafsson 1973) and
that the substrates of the activated enzymes
were relatively nonspecific. In 1998, activation
of human CYP3A4 was shown to be primarily
mediated by nuclear receptor subfamily 1,
group I, member 2 [NR1I2; GenBank acces-
sion no. AY091855; National Center for
Biotechnology Information (NCBI) 2007b].
For purposes of clarification, we use the trivial
names of NR1I2 orthologs associated with
specific taxonomic groups. This receptor is
commonly known as the steroid and xeno-
biotic receptor (SXR) in primates (Blumberg
et al. 1998), pregnane X receptor (PXR) in
nonprimate mammals (Kliewer et al. 1998;
Lehmann et al. 1998), chicken X receptor
(CXR) in birds (Moore et al. 2002), and ben-
zoate X receptor (BXR) in amphibians (Grün
et al. 2002). It is now well established that the
most prevalent CYP enzymes in the liver,
members of the CYP3A and 2B subfamilies,
along with a host of conjugating enzymes and
ATP binding cassette (ABC) family mem-
brane transport proteins, are under direct
transcriptional regulation by NR1I2 (Xie et al.
2000b, 2004).
Through the action of its target genes,
NR1I2 is a key regulator of bile salt, steroid
hormone, and xenobiotic metabolism and
excretion (Kliewer et al. 2002). NR1I2 is a
member of the nuclear hormone receptor
superfamily, which also includes sex steroid
receptors, thyroid receptor, and other orphan
receptors such as constitutive androstane
receptor (CAR, NR1I3). The term “orphan
receptor” has been given to a number of tran-
scription factors that are related to nuclear
receptors but for which a definitive endogenous
ligand was not initially identified. Ligand-
dependent activation of NR1I2 is mediated by
steroid hormones, dietary compounds (e.g.,
phytoestrogens), vitamins E and K, medicinal
herbs, xenobiotics, and approximately 50% of
prescription drugs (reviewed by Dussault and
Forman 2002; Kretschmer and Baldwin 2005).
These ligands are extremely varied in chemical
structure and application, and some have been
shown to activate or antagonize NR1I2
orthologs in a species-specific manner (e.g.,
rifampicin, coumestrol, highly chlorinated
polychlorinated biphenyls) (Blumberg et al.
1998; Jones et al. 2000; Tabb et al. 2004).
Development of the so-called humanized
mouse was an important step in understand-
ing the pharmacology of xenobiotic metabo-
lism (Xie et al. 2000a). This animal is
deficient in the rodent NR1I2 ortholog, PXR,
and transgenic for human SXR expression in
the liver. This model demonstrates convinc-
ingly that NR1I2 is the key regulator of
CYP3A expression and that selective activation
of target genes in response to species-specific
activators depends on the ligand-binding
domain (LBD) of this receptor, rather than
on the DNA-binding domain (DBD) or tar-
get DNA-binding elements. The primary
sequence of the LBD for NR1I2 varies greatly
across species. The sequence similarity can be
as low as 75% between mammalian NR1I2
orthologs and as low as 49% when comparing
the chicken ortholog, CXR, to human SXR
(Moore et al. 2002). A fundamental assump-
tion made when using the results of model ani-
mal experiments to predict effects on humans
or wildlife is that uptake and metabolism of
the compound as well as the biochemistry
and endocrinology of the organism is similar
between the model species and species of
concern. In some cases, the response of a
model species to chemical exposure is reason-
ably predictive of the effects on humans. In
other cases, the connection is more uncertain,
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BACKGROUND: Nuclear receptor subfamily 1, group I, member 2 (NR1I2), commonly known as
steroid and xenobiotic receptor (SXR) in humans, is a key ligand-dependent transcription factor
responsible for the regulation of xenobiotic, steroid, and bile acid metabolism. The ligand-binding
domain is principally responsible for species-specific activation of NR1I2 in response to xenobiotic
exposure.
OBJECTIVES: Our objective in this study was to create a common framework for screening NR1I2
orthologs from a variety of model species against environmentally relevant xenobiotics and to evalu-
ate the results in light of using these species as predictors of xenobiotic disposition and for assess-
ment of environmental health risk.
METHODS: Sixteen chimeric fusion plasmid vectors expressing the Gal4 DNA-binding domain and
species-specific NR1I2 ligand-binding domain were screened for activation against a spectrum of
27 xenobiotic compounds using a standardized cotransfection receptor activation assay.
RESULTS: NR1I2 orthologs were activated by various ligands in a dose-dependent manner. Closely
related species show broadly similar patterns of activation; however, considerable variation to indi-
vidual compounds exists, even among species varying in only a few amino acid residues.
CONCLUSIONS: Interspecies variation in NR1I2 activation by various ligands can be screened
through the use of in vitro NR1I2 activation assays and should be taken into account when choos-
ing appropriate animal models for assessing environmental health risk.
KEY WORDS: endocrine disruption, metabolism, pesticides, phthalates, PXR, SXR, xenobiotics.
Environ Health Perspect 116:880–885 (2008). doi:10.1289/ehp.10853 available via http://dx.doi.org/
[Online 12 March 2008]
and the ability to predict risk is not reliable.
Understanding how the xenobiotic response
differs among species is essential to developing
high-quality models and characterizations of
risk from chemical exposure.
The goal of this study was to screen a
wide variety of xenobiotic compounds for
interaction with NR1I2 orthologs within a
common system, thus providing the frame-
work for understanding the metabolism of
xenobiotics in different model species. To
compare responses correlating to interspecies
variation in the LBD of NR1I2, we used an
in vitro luciferase reporter assay driven by
yeast Gal4 DBD-NR1I2 LBD fusion plas-
mids. Advantages of this system are that it
eliminates the need to clone each species’
bona fide response and is insensitive to induc-
tion by endogenous receptors. One disadvan-
tage of this system is that it is insensitive to
interspecies variation in activation function-1
(AF-1) region coregulator recruitment; how-
ever, the availability of coregulators in any
in vitro system is not necessarily representative
of the in vivo environment. A structurally
diverse array of xenobiotics was chosen
(Table 1) to represent a broad spectrum of
chemical classes and applications that pub-
lished data indicate are of considerable envi-
ronmental and/or health concern. NR1I2
orthologs tested included commonly used
laboratory, toxicologic, and/or genome model
species. The results of these experiments have
important implications for determining the
appropriate use of animal models and for
assessing whether we can reasonably rely on
those models to predict results in other
species, including humans.
Materials and Methods
Cloning of NR1I2 orthologs. LBD coding
sequence has previously been reported in
GenBank for NR1I2 orthologs in human
(accession no. AY091855), dog (AF454670),
rabbit (AF182217), rat (AF151377), mouse
(NM010936), chicken (AF276753), Xenopus
laevis BXRα (BC041187) and BXRβ
(AF305201), and zebrafish (AF502918). Novel
NR1I2 LBD sequences were cloned from
Japanese macaque (Macaca fuscata), crab-eating
macaque (Macaca fascicularis), marmoset
(Callithrix jacchus), quail (Coturnix japonica),
fathead minnow (Pimephales promelas), fugu
(Takifugu rubripes), and medaka (Oryzias
latipes). For novel sequences, optimized degen-
erate primers (forward 5´-AGAACTAGTG-
GATCCGYGARGGNTGYAARGGNTTYT
T and reverse 5´-GGTATCGATAAGCTTG-
CYTGCATNARNACRTAYTCYTC) were
used for polymerase chain reaction (PCR)
amplification of a region extending from the
first zinc finger of the DBD (C E G C K G F
F) into the LBD (E E Y V L M Q A) for each
species. We used nested primers derived from
the amplified region and 3´-RACE (rapid
amplification of cDNA ends) to obtain full
LBD sequences beginning with the coding
region corresponding to human SXR Met-107
from liver cDNA libraries from each species.
Gal4-NR1I2 fusion constructs were created by
subcloning the LBD into EcoRI and BamHI
sites of the vector pCMX-Gal4N (Blumberg
et al. 1998) using ExoIII-mediated ligation-
independent cloning (Li and Evans 1997). The
PCR products were directly sequenced, and we
selected GAL4-NR1I2 LBD clones that
matched each consensus sequence.
Cell culture and luciferase reporter assays.
COS7 cells were maintained in phenol-red–
free Dulbecco’s minimal Eagle medium
(DMEM) supplemented with 10% fetal
bovine serum (FBS). Twenty-four hours
before transfection, we seeded 96-well plates
with 5 × 105 cells per plate. Chimeric receptor
plasmids were cotransfected along with the
tk(MH100)x4luc and pCMX-β-galactosidase
reporter plasmids using calcium-phosphate–
mediated transfection (Grün et al. 2002; Tabb
et al. 2004). All ligands were initially dissolved
in dimethylsulfoxide (DMSO) and subse-
quently diluted in DMEM supplemented with
10% charcoal-resin stripped FBS with a final
concentration of 0.5% DMSO. The final
DMSO concentration was minimized accord-
ing to the solubility limits of the test com-
pounds and adjusted so that all treatments
were carried out under the same conditions.
No overt toxicity, as indicated by β-galactosi-
dase activity, was observed relative to untreated
controls. After 24 hr of ligand exposure, we
assayed 50-µL aliquots of cell lysate for
luciferase and β-galactosidase activity, as previ-
ously described (Grün et al. 2002). Luciferase
activity is reported as fold activation relative to
the vehicle control (0.5% DMSO) and nor-
malized for β-galactosidase activity. Each com-
bination of receptor and ligand was run in
triplicate at three doses and repeated whenever
the coefficient of variance exceeded 0.15.
Positive control ligands were assigned based on
previously published data or empirically deter-
mined upon cloning of the novel orthologs.
We also ran a negative control consisting of
vector lacking an NR1I2 LBD for each ligand
to ensure luciferase activity was not promoted
via LBD-independent pathways.
Sequence alignment and phylogenetic
analysis. Novel sequences were checked for
similarity using blastn and blastp (NCBI
2007a) and submitted to GenBank (NCBI
2007b). We used ClustalX (Thompson et al.
1997) to align deduced amino acid LBD
sequences and create an identity matrix. A
neighbor-joining phylogenetic tree was con-
structed using the PHYLIP computer program
(Felsenstein 1989) using NR1I3 as a closely
related outgroup.
Results
NR1I2 ortholog sequences. Comparison of
NR1I2 ortholog LBD sequences (Figure 1)
revealed a relatively high degree of similarity
among mammalian orthologs compared to
nonmammals. Human SXR amino acid
Interspecies variation in SXR
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Table 1. Compounds tested for their ability to activate NR1I2 orthologs.
Compound Classification CAS no. Supplier
4-tert-Octylphenol Alkyl phenol 140-66-9 Wako Pure Chemical Industries, Osaka, Japan
Carbaryl Carbamate 63-25-2 ChemService, West Chester, PA, USA
Pentachlorophenol Chlorinated phenol 87-86-5 Wako Pure Chemical Industries, Osaka, Japan
2,4-Dichlorophenol Chlorinated phenol 120-83-2 Tokyo Chemical Industry, Japan
Benzophenone Industrial intermediate 119-61-9 ChemService, West Chester, PA, USA
4-Nitrotoluene Industrial intermediate 99-99-0 Tokyo Chemical Industry, Tokyo, Japan
Chlordane Organochlorine 57-74-9 ChemService, West Chester, PA, USA
Dieldrin Organochlorine 60-57-1 ChemService, West Chester, PA, USA
p,p´-DDE Organochlorine 72-55-9 ChemService, West Chester, PA, USA
Methoxychlor Organochlorine 72-43-5 ChemService, West Chester, PA, USA
o,p´-DDT Organochlorine 789-02-6 ChemService, West Chester, PA, USA
Toxaphene Organochlorine 8001-35-2 ChemService, West Chester, PA, USA
Endosulfan Organochlorine 115-29-7 ChemService, West Chester, PA, USA
Octachlorostyrene Organohalogen 29082-74-4 ChemService, West Chester, PA, USA
Tributyl tin chloride Organotin 1461-22-9 Sigma-Aldrich, St. Louis, MO, USA
Triphenyl tin chloride Organotin 639-58-7 Sigma-Aldrich, St. Louis, MO, USA
Dibutyl phthalate Phthalate 84-74-2 Wako Pure Chemical Industries, Osaka, Japan
Benzyl butyl phthalate Phthalate 85-68-7 Wako Pure Chemical Industries, Osaka, Japan
Bis (2-ethylhexyl) phthalate Phthalate 117-81-7 Wako Pure Chemical Industries, Osaka, Japan
Dicyclohexyl phthalate Phthalate 84-61-7 Wako Pure Chemical Industries, Osaka, Japan
Diethyl phthalate Phthalate 84-66-2 Kanto Chemical Company, Tokyo, Japan
Di-n-hexyl phthalate Phthalate 84-75-3 Tokyo Chemical Industry, Tokyo, Japan
n-Dipentyl phthalate Phthalate 131-18-0 Tokyo Chemical Industry, Tokyo, Japan
n-Dipropyl phthalate Phthalate 131-16-8 Tokyo Chemical Industry, Tokyo, Japan
Bisphenol A Plastic monomer 80-05-7 Tokyo Chemical Industry, Tokyo, Japan
Fenvalerate Pyrethroid 51630-58-1 ChemService, West Chester, PA, USA
Amitrol Triazine 61-82-5 ChemService, West Chester, PA, USA
CAS, Chemical Abstracts Service; p,p´-DDE, p,p´-dichlorodiphenyldichloroethylene; o,p´-DDT, o,p´ dichlorodiphenyl-
trichloroethane. 
residues that line the LBD and interact with
various ligands (shaded) have been character-
ized by X-ray crystallography (Chrencik et al.
2005; Watkins et al. 2001, 2003). The corre-
sponding residues appear to be highly con-
served within mammals or are typically
represented by functionally similar amino
acid substitutions such as nonpolar valine,
leucine, and methionine, or polar serine and
threonine. Notable exceptions include the
substitution of serine for leucine at position
105 in rodents and leucine or isoleucine for
glutamine at position 184 in rabbits and
rodents. When comparing nonmammalian
NR1I2 orthologs, the least conserved region
is the helix 1–3 insert, almost entirely absent
in Xenopus BXRs, and highly variable among
avian CXRs and fish orthologs. This region is
thought to facilitate expansion of the ligand-
binding pocket and distinguishes NR1I2
from functionally divergent members of the
NRI1 family (Moore et al. 2002).
Sequence similarity and associations
observed in the neighbor-joining tree
(Figure 2) are generally consistent with
expected evolutionary relationships among the
represented vertebrate classes and orders. These
results also indicate that the nonmammalian
orthologs are approximately equidistant from
mammalian NR1I2 and NR1I3, consistent
with the hypothesis that mammalian NR1I2
and NR1I3 resulted from a gene duplication of
a nonmammalian ancestral ortholog
(Handschin et al. 2004; Krasowski et al. 2005).
Activation of NR1I2 othologs. All ligands
(with the exception of organotins) were
screened at concentrations of 0.5, 5, and
50 µM. Of the 27 xenobiotic compounds
tested, phthalates and organochlorines were
most effective at activating NR1I2 orthologs.
Human SXR and murine PXR were readily
activated by most phthalates at 5 µM
(Table 2), whereas amphibian, zebrafish, fugu,
and medaka orthologs were for the most part
unaffected, even at the highest concentrations.
At 50 µM, all organochlorines except
octachlorostyrene induced a > 10-fold increase
in luciferase activity relative to vehicle alone in
many species (Table 3). Nonprimate
mammalian, avian, and amphibian NR1I2
orthologs appeared most susceptible to
organochlorine activation and exhibited
moderate (4- to 10-fold) to high luciferase
activity at 5 µM. With the exception of
2,4-dichlorophenol in medaka, most NR1I2
orthologs were completely insensitive to chlo-
rinated phenols. The organotins, which are
cytotoxic at micromolar concentrations, were
tested at 1, 10, and 100 nM and failed to
induce significant luciferase activity in any
species (Table 4). Among the nonorgano-
chlorine pesticides and industrial compounds,
only the pyrethroid ester fenvalerate and the
alkyl phenol surfactant 4-tert-octylphenol
elicited significant luciferase activity at the
5-µM concentration.
Milnes et al.
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Figure 1. Alignment of amino acid sequences of NR1I2 ortholog LBDs. Shaded regions correspond to amino acid residues of the LBD that have been shown to
interact with xenobiotic ligands in human SXR (Chrencik et al. 2005; Watkins et al. 2001, 2003). The boxed regions represent the helix 1–3 insert that distinguishes
functionally divergent members of the NR1I subfamily (Moore et al. 2002). J. macaque, Japanese macaque; C.E. macaque, crab-eating macaque. 
Discussion
Our results show significant variability across
species in the capacity of xenobiotics to activate
NR1I2 orthologs. Generally speaking, NR1I2
exhibits broad ligand specificity and regulates
genes involved in hepatic metabolism of
endogenous and xenobiotic compounds. As a
result, this transcription factor presents unique
challenges with regard to pharmacology 
and toxicology. For instance, the antibiotic
rifampicin, a potent and selective activator of
human SXR, can up-regulate hepatic metabo-
lism of steroids to the extent that patients were
incorrectly diagnosed with Cushing’s syndrome
following overnight dexamethasone suppression
tests (Kyriazopoulou and Vagenakis 1992).
Furthermore, activation of SXR by one thera-
peutic compound can significantly alter the fate
of another. Rifampicin and the herbal supple-
ment St. John’s wort have both been shown to
increase the clearance of the oral contraceptives
ethinylestradiol and norethindrone (Barditch-
Crovo et al. 1999; Hall et al. 2003).
Compounds that activated human SXR
also activated SXR in nonhuman primates,
but fold induction relative to the vehicle was
typically lower in these species. In contrast, the
nonprimate mammalian orthologs exhibited
higher relative activation for many organochlo-
rines and phthalates when compared to human
SXR. Although fold induction of luciferase
activity was variable across species for each lig-
and, all mammalian, avian, and amphibian
orthologs appeared to be suitable qualitative
models for predicting activation of human SXR
with organochlorines. The two Xenopus BXRs
had activation profiles similar to each other but
were much less predictive of the human SXR
response to phthalates compared to mammalian
Interspecies variation in SXR
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Table 2. Species-specific activation of NR1I2 orthologs by phthalates.
Exposure Japanese Crab-eating X. laevis X. laevis
Ligand (µM) Human macaque macaque Marmoset Dog Mouse Rat Rabbit Chicken Quail BXRα BXRβ FHM Zebrafish Fugu Medaka
Diethyl phthalate 50 2.7 1.1 1.4 1.4 1.5 0.8 1.7 1.4 1.6 2.2 0.9 0.5 14.4 3.3 1.3 5.1
5 1.0 0.6 0.7 0.8 1.0 0.5 0.9 0.7 0.9 1.0 0.7 1.0 2.4 0.7 1.1 3.3
0.5 0.8 1.4 0.9 0.9 1.1 2.5 0.8 0.9 1.0 0.7 2.5 0.7 0.8 1.1 1.1 1.7
Benzyl butyl 50 11.4 4.8 3.6 4.4 12.0 23.6 18.9 12.0 7.1 10.1 3.1 2.0 8.5 1.8 1.6 1.4
phthalate 5 4.5 3.6 4.0 3.1 1.6 5.1 7.0 3.3 3.3 8.6 1.8 1.4 3.8 1.0 1.5 1.1
0.5 1.0 1.4 1.3 1.0 1.4 1.1 1.1 0.9 1.2 1.7 1.0 0.7 1.0 0.7 0.8 1.0
Bis (2-ethylhexyl) 50 13.0 6.8 3.6 3.7 12.8 35.3 28.1 10.5 10.5 6.8 3.5 4.2 2.8 1.4 2.7 2.4
phthalate 5 10.7 12.4 9.8 5.8 3.5 33.6 30.0 6.7 6.3 6.3 1.9 3.8 1.7 1.1 3.7 2.3
0.5 1.9 3.8 5.3 1.9 1.1 2.5 3.8 1.9 1.5 1.2 1.5 1.2 1.1 0.8 1.3 1.1
Dicyclohexyl 50 11.0 4.1 2.7 3.0 11.1 16.6 16.2 7.8 9.2 6.3 2.9 3.2 2.0 1.5 1.5 1.6
phthalate 5 10.1 5.5 5.8 5.7 3.7 12.1 10.4 3.0 5.8 7.9 1.9 2.9 1.6 2.7 2.5 1.3
0.5 1.8 1.5 1.7 1.5 1.3 1.3 1.4 1.1 1.3 1.5 0.7 1.1 1.1 0.8 1.1 1.2
Dibutyl 50 10.9 4.2 4.5 4.2 9.9 19.6 19.5 10.5 7.9 5.4 2.3 1.0 14.1 2.7 1.6 1.9
phthalate 5 3.6 2.4 2.9 2.9 2.0 2.5 4.2 2.5 2.2 3.3 0.9 1.1 5.1 1.9 1.4 1.6
0.5 2.5 1.4 1.1 1.0 1.0 0.7 1.1 1.1 1.1 0.9 1.1 1.1 0.9 0.8 1.0 1.0
n-Dipentyl 50 10.7 2.8 3.6 4.6 4.8 15.3 22.6 6.5 7.8 7.2 3.4 1.8 7.8 1.7 1.8 2.0
phthalate 5 2.6 2.9 4.0 4.1 0.6 4.2 5.9 2.2 2.9 7.5 3.4 1.4 1.6 0.8 2.4 1.5
0.5 1.8 2.1 1.6 2.2 0.7 1.0 1.2 1.0 1.0 1.7 1.5 1.0 1.7 1.2 1.1 2.1
n-Dipropyl 50 8.1 4.0 4.6 6.3 2.0 8.8 12.3 4.4 6.8 5.7 5.0 1.0 36.2 6.2 2.3 5.7
phthalate 5 2.5 1.3 1.9 2.8 0.4 1.5 2.2 1.4 1.4 2.5 3.1 1.3 13.6 4.0 1.2 5.5
0.5 2.2 0.7 1.0 1.4 0.4 1.0 1.1 0.7 0.9 1.1 1.1 0.8 2.4 0.6 1.3 2.3
Di-n-hexyl 50 10.6 3.7 3.7 5.1 3.4 20.1 21.4 4.9 9.5 10.5 4.3 2.5 6.4 1.6 2.4 1.5
phthalate 5 3.9 3.1 5.6 4.8 0.8 4.7 7.4 3.2 2.2 6.9 2.2 1.7 2.2 0.9 2.7 1.2
0.5 1.2 1.0 1.8 1.9 0.5 0.9 1.1 0.7 1.0 1.5 2.0 1.1 1.1 0.7 1.5 1.4
Positive controla 50 22.8 5.9 7.3 14.6 17.8 68.6 41.3 10.2 17.7 22.8 32.1 94.0 — — 5.8 12.8
5 16.3 4.3 5.0 7.7 2.8 64.2 39.8 3.1 5.7 14.7 22.7 49.8 34.1 6.2 4.9 8.0
0.5 3.7 1.6 2.2 2.6 1.4 36.7 26.6 1.0 1.0 4.4 10.9 8.8 24.2 3.0 2.4 2.6
FHM, fathead minnow. Values represent fold induction of luciferase activity (normalized for β-galactosidase activity) relative to DMSO treatment. 
aPositive controls were as follows: rifampicin for human, macaque, dog, marmoset, rabbit, and fugu; pregnenolone 16α-carbonitrile for mouse and rat; 5β-3,20 pregnane dione for
chicken and quail; p-hydroxy benzoic acid butyl ester for Xenopus laevis BXRα and BXRβ, and medaka; and clotrimazole (cytotoxic at 50 µM) for FHM and zebrafish. 
Figure 2. Nonrooted neighbor-joining tree of NR1I2 orthologs and mammalian NR1I3 ligand-binding domains (A), and the percent amino acid identities of NR1I2
otholog ligand-binding domains (B). Abbreviations: FHM, fathead minnow; J. macaque, Japanese macaque; C.E. macaque, crab-eating macaque.
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and avian orthologs. In contrast, responses
among fish orthologs were so variable that few
if any generalizations could be made. Medaka
appeared to be insensitive to the vast majority
of compounds tested, whereas the fathead
minnow appears to be the most relevant model
with regard to human SXR activation.
An important aspect of interpreting the
toxicologic relevancy of these data is the com-
parison of the concentrations that elicit in vitro
activation to predicted environmental expo-
sure. One major limitation to analysis is that
there is a relative paucity of data concerning
the concentrations of chemicals in blood and
other biological fluids in response to particular
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Table 3. Species-specific activation of NR1I2 orthologs by organochlorines and phenols.
Exposure Japanese Crab-eating X. laevis X. laevis
Ligand (µM) Human macaque macaque Marmoset Dog Mouse Rat Rabbit Chicken Quail BXRα BXRβ FHM Zebrafish Fugu Medaka
Chlordane 50 5.7 3.1 4.4 7.8 21.3 20.7 12.0 12.1 9.5 7.5 17.9 7.2 14.4 4.5 2.7 0.5
5 8.9 3.7 3.3 5.8 5.1 10.8 14.4 6.7 5.3 10.6 4.3 5.1 7.9 2.4 3.0 0.8
0.5 2.3 1.1 1.4 2.6 1.4 2.2 2.7 2.6 1.5 4.0 1.2 1.6 1.8 0.9 1.1 0.7
o,p’-DDT 50 16.3 5.1 6.9 12.3 27.0 45.3 32.3 12.6 17.3 23.8 16.7 15.8 11.9 4.0 9.1 1.3
5 6.2 1.6 2.1 4.1 1.0 3.0 3.4 1.6 3.6 7.4 2.0 2.6 2.4 1.3 1.6 1.1
0.5 1.3 1.1 1.1 1.0 0.8 1.1 0.6 0.9 1.2 1.3 1.1 1.2 1.1 1.0 1.3 1.2
p,p´-DDE 50 15.4 2.8 8.5 12.0 5.3 8.6 9.6 3.8 12.6 7.4 5.4 8.6 1.8 1.1 4.3 1.1
5 2.1 1.2 1.4 2.2 0.7 1.2 1.1 1.0 1.7 1.6 1.4 1.7 1.4 0.6 1.1 1.1
0.5 1.2 0.8 0.8 1.2 0.9 1.3 0.7 0.9 1.1 1.0 0.9 1.3 1.0 0.9 0.9 1.1
Dieldrin 50 11.0 3.4 5.9 11.6 9.8 33.0 25.7 16.3 10.4 13.8 9.3 4.8 5.6 1.6 2.8 0.2
5 7.0 1.3 3.8 5.7 2.8 8.2 7.4 11.6 2.7 9.0 2.5 3.6 2.1 1.0 1.7 0.3
0.5 2.0 1.1 1.3 3.3 1.0 1.5 1.6 2.2 1.4 3.4 1.3 1.8 2.2 1.0 1.0 0.5
Endosulfan 50 8.5 4.6 4.7 14.6 17.5 50.7 29.9 16.8 17.8 15.4 18.0 9.9 7.1 3.5 2.8 0.3
5 4.7 2.6 3.1 5.6 1.3 7.0 9.1 8.6 3.3 7.8 1.9 3.0 2.5 1.0 1.4 0.3
0.5 1.5 1.2 1.5 2.3 2.4 1.7 1.5 1.7 1.1 2.4 1.1 1.3 1.8 1.0 1.1 0.8
Methoxychlor 50 22.3 4.1 10.6 21.8 12.5 110.0 57.9 16.1 24.8 20.8 11.2 9.4 7.1 3.4 7.1 0.6
5 3.9 1.5 2.4 3.9 1.0 16.5 29.8 2.5 3.5 5.2 1.7 2.5 2.0 1.4 1.3 1.0
0.5 1.2 1.2 0.7 1.5 0.8 1.3 1.0 0.9 1.2 2.0 1.1 1.4 1.4 1.2 0.9 1.4
Octachlorostyrene 50 8.5 3.1 2.4 2.9 3.5 5.2 6.6 2.1 3.7 3.9 2.7 1.0 1.2 0.9 1.3 1.3
5 1.3 1.0 1.1 1.2 1.4 1.2 1.4 0.9 1.1 2.3 0.7 0.7 1.9 0.6 1.3 1.2
0.5 1.4 0.9 0.8 0.9 0.8 0.6 0.9 0.9 1.0 1.4 0.6 0.6 1.7 1.1 1.0 1.4
Toxaphene 50 10.9 5.1 6.5 16.3 41.9 38.2 22.4 16.3 16.0 25.8 21.5 12.5 19.8 5.5 2.8 0.8
5 8.5 4.1 4.8 10.7 7.5 17.2 17.8 6.3 8.0 14.0 5.1 8.3 14.9 3.1 3.3 0.8
0.5 1.9 1.1 1.3 2.6 0.7 2.3 1.9 0.9 1.7 4.7 1.3 1.8 3.7 1.2 1.1 1.0
2,4-Dichlorophenol 50 1.0 0.6 0.9 1.3 0.4 1.3 0.9 0.9 1.1 0.8 2.5 0.7 0.9 0.6 0.8 2.7
5 1.1 0.8 1.1 1.4 0.3 1.2 0.9 0.7 1.0 1.0 1.4 0.8 1.8 0.7 1.0 5.0
0.5 0.9 0.8 1.2 1.4 0.5 0.7 1.0 0.7 1.1 1.3 0.9 0.9 1.7 1.0 1.1 5.7
Pentachlorophenol 50 0.8 0.9 1.4 1.3 0.3 1.5 1.0 0.7 0.7 0.9 1.3 1.4 0.8 0.5 1.0 1.3
5 1.7 0.9 1.5 1.2 0.4 3.1 1.0 0.6 0.8 1.0 2.3 1.1 1.0 0.8 1.2 1.1
0.5 0.8 0.8 1.0 1.1 0.4 0.6 1.0 0.7 1.1 0.9 2.8 0.9 0.7 0.7 1.1 1.2
FHM, fathead minnow. Values represent fold induction of luciferase activity (normalized for β-galactosidase activity) relative to DMSO treatment. 
Table 4. Species-specific activation of NR1I2 orthologs by selected nonorganochlorine pesticides, organotins, and industrial compounds.
Exposure Japanese Crab-eating X. laevis X. laevis
Ligand (µM) Human macaque macaque Marmoset Dog Mouse Rat Rabbit Chicken Quail BXRα BXRβ FHM Zebrafish Fugu Medaka
4-Nitrotoluene 50 2.1 0.6 1.1 1.5 0.4 1.6 1.2 0.9 1.3 1.1 2.3 0.9 1.0 0.9 1.4 6.6
5 1.0 0.8 1.0 1.4 0.4 1.1 1.3 1.1 1.0 0.9 2.1 1.1 1.3 0.7 1.4 5.1
0.5 0.8 1.2 1.0 1.7 0.7 0.8 1.0 2.0 1.6 1.0 1.1 1.1 1.3 0.7 1.8 2.0
4-tert- 50 15.9 3.5 4.0 7.3 12.8 13.4 20.4 7.5 8.7 7.7 12.5 5.2 17.1 4.6 3.3 6.0
Octylphenol 5 10.2 2.0 3.2 4.4 2.4 1.7 2.3 1.4 5.4 6.5 4.8 2.3 6.0 3.1 3.6 6.4
0.5 1.3 1.0 1.5 1.6 0.5 0.7 1.0 1.0 1.4 2.6 1.1 1.2 1.4 0.9 1.5 6.7
Amitrol 50 0.7 1.0 0.8 1.1 0.3 2.2 1.0 0.5 1.0 1.3 1.7 0.8 0.9 0.7 1.1 4.2
5 2.0 0.7 1.1 1.7 0.5 0.6 0.9 0.7 1.0 1.4 1.4 0.7 1.1 0.9 1.7 6.5
0.5 4.3 2.3 1.6 2.2 0.9 1.3 1.3 2.6 1.5 4.6 3.0 1.2 3.5 1.0 1.5 6.3
Bisphenol A 50 11.0 3.8 3.7 5.4 1.0 3.0 2.5 4.8 9.2 6.3 6.0 5.3 2.8 2.3 4.9 3.5
5 1.9 0.7 0.8 1.5 0.3 0.8 1.8 1.3 1.6 1.5 1.3 1.2 0.8 0.8 1.1 3.2
0.5 0.9 0.7 0.8 1.1 0.4 0.9 1.0 0.7 1.1 1.2 1.2 0.8 0.8 0.8 1.6 2.1
Benzophenone 50 1.1 1.4 1.2 1.3 0.9 0.8 1.2 0.8 2.1 2.5 20.0 0.5 1.6 0.7 0.8 1.8
5 0.9 1.1 0.8 0.9 1.9 0.9 0.8 0.7 1.1 1.3 7.9 0.7 1.1 0.8 1.0 1.5
0.5 1.5 1.3 0.9 0.9 1.1 1.0 1.3 2.0 1.1 2.1 1.3 0.7 1.1 0.5 0.9 1.2
Carbaryl 50 2.3 0.9 1.9 3.0 1.8 1.8 1.2 2.3 1.5 2.1 1.7 1.6 2.0 1.4 1.2 1.7
5 1.5 0.8 1.1 1.5 0.9 1.4 0.9 1.4 1.5 2.3 1.1 2.0 1.4 1.4 0.9 0.8
0.5 2.8 1.5 2.1 2.6 1.2 2.3 2.0 1.9 1.9 3.9 1.6 2.3 2.7 1.3 1.4 0.8
Fenvalerate 50 13.7 6.6 10.4 19.8 60.7 65.9 41.7 32.8 23.5 23.3 11.6 11.8 4.0 6.2 8.4 1.0
5 12.6 4.1 6.6 8.4 5.2 29.2 28.6 7.8 11.6 9.7 5.2 6.1 3.4 3.1 4.1 1.0
0.5 2.0 0.9 1.8 2.0 1.0 1.6 1.9 1.6 1.6 1.6 1.2 1.3 1.4 0.9 1.0 1.0
Tributyl tin 100 2.0 0.8 0.9 0.7 1.3 1.4 0.6 1.4 1.3 0.9 0.7 1.8 0.6 0.7 0.5 0.9
chloride 10 0.9 1.0 0.8 0.7 1.2 1.0 0.6 0.7 1.3 1.3 0.8 1.2 0.6 0.7 0.8 0.9
1 0.9 0.8 0.8 0.8 0.8 0.7 1.0 1.2 1.1 0.8 0.7 0.9 0.9 0.4 1.0 1.1
Triphenyl tin 100 0.5 1.0 0.8 1.3 1.1 0.6 0.7 2.7 1.4 0.9 0.9 1.0 0.8 2.0 1.7 0.9
chloride 10 1.1 0.7 0.9 0.9 1.6 0.3 1.4 1.0 0.9 0.8 0.6 1.2 1.3 0.9 1.9 1.1
1 0.7 1.0 1.0 0.8 1.2 0.4 0.8 2.1 0.9 1.0 0.6 1.1 0.9 0.8 1.2 1.2
FHM, fathead minnow. Values represent fold induction of luciferase activity (normalized for β-galactosidase activity) relative to DMSO treatment. 
environmental concentrations. Another limita-
tion to meaningful comparisons is that the
method of reporting concentrations in biologi-
cal and environmental samples is quite vari-
able. For instance, the concentrations of many
of the same organochlorine pesticides and
phthalates used in this study have been mea-
sured in human breast milk as an indicator of
neonatal exposure. The concentrations of
organochlorines and other lipophilic com-
pounds are reported as nanograms per gram
lipid, and the major metabolites of phthalates,
phthalate monoesters, are reported micrograms
per liter. Assuming an average of 3–4% lipid in
breast milk (Needham and Wang 2002),
molar concentrations of organochlorines such
as methoxychlor and o,p´-DDT were typically
< 1 nM, whereas endosulfan and p,p´-DDE
were in the 10–50 nM range (Damgaard et al.
2006; Shen et al. 2008). Although concentra-
tions in breast milk are an order of magnitude
lower than the minimum dose tested (500 nM),
the daily intake of the infant should also be con-
sidered. Nanomolar to low micromolar concen-
trations were reported for phthalate monoesters
in the breast milk of Danish and Finnish
women (Main et al. 2006). Based on the con-
centrations in breast milk, infant body mass,
and average milk consumption, the range of the
estimated daily intake of some phthalates
exceeded 50 µg/kg/day, the same dose used to
up-regulate PXR-responsive genes with known
ligands in laboratory mice (Xie et al. 2000a).
Although the toxicologic effects of activat-
ing NR1I2 are not completely understood, the
metabolic pathways regulated by NR1I2 impli-
cate it as a potential target for disrupting bile
acid and steroid homeostasis (Zhai et al. 2007).
Further complicating these interactions, xeno-
biotics that fail to activate this receptor may be
more toxic than those that activate it and
induce their own metabolism. NR1I2 mediates
the metabolism of many drugs, and this
metabolism can be induced to a very high level
by chronic NR1I2 activation. Mice expressing
a constitutively active form of human SXR
(Alb-VPSXR) are almost completely resistant
to the anesthetic effects of tribromoethanol and
zoxaolamine, demonstrating this concept (Xie
et al. 2000a).
The development of competitive binding
and receptor activation assays allows one to
estimate the potential for a xenobiotic com-
pound to interact with a single receptor in any
species. However, the ability to predict which
chemicals will induce a characterized response
in vivo at a particular dose, such as uterine pro-
liferation via estrogen receptor (ER) activation,
is much more complex. This matter is further
complicated when considering exposure to a
chemical that activates multiple transcription
factors with different affinities. For instance,
bisphenol A has an EC50 (half maximal con-
centration) of approximately 200 nM in ER
luciferase reporter assays and the E-Screen cell
proliferation assay (Gutendorf and Westendorf
2001). Our data indicate that bisphenol A acti-
vates NR1I2-dependent transcription at
50 µM and thus would induce its own metab-
olism at similar concentrations. Based on these
data, one might predict an inverted U-shaped
dose–response curve for bisphenol A in vivo, a
phenomenon that has been repeatedly reported
(for review, see vom Saal and Hughes 2005).
A significant difficulty in deriving an accu-
rate risk assessment from laboratory experiments
is the uncertainty about whether the underlying
mechanisms of response to chemical exposure
are universal. The use of in vitro or cell-based
assays to guide and refine the development of
in vivo models to screen compounds for NR1I2
activation is a useful tool to understand and/or
prevent unintended xenobiotic interactions.
Our results demonstrate species-specific differ-
ences in the ability of NR1I2 orthologs to
activate transcription. This suggests that the
metabolism, and presumably the physiological
effects, of those ligands will also vary across
species. Future work screening xenobiotics for
toxicologic effects as well as drug–drug interac-
tions should take these data into consideration.
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